Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of tulisokibart in moderately to severely active Crohn's disease
2024-518296-56-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 46
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing tulisokibart with placebo to MK-7240 (2 arms). Primary endpoints: Percentage of participants achieving clinical remission per Crohn's Disease Activity Index score at Week 12, Percentage of participants achieving clinical remission per stool frequency and abdominal pain score at Week 12 and 1 more. Planned start Sep 2025; status: authorised.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-518296-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518296-56-00.